Characterization of LECT2, A Potential Drug Target for Neurodegenerative Diseases

Target Name: LECT2

NCBI ID: G3950

LECT2

Characterization of LECT2, A Potential Drug Target for Neurodegenerative Diseases

LECT2 (Chm2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell receptor family and is involved in the immune response. LECT2 has been identified as a potential drug target (or biomarker) due to its unique structure and its involvement in several disease processes.

The protein encoded by the LECT2 gene is a 21-kDa protein that consists of an N-terminus of 20 amino acids, a single transmembrane segment, and a C-terminus of 11 amino acids. It has a molecular weight of 21 kDa and a calculated pI of 4.8. LECT2 is predominantly expressed in the brain, heart, and kidneys, with lower levels of expression in the liver and spleen.

LECT2 is involved in several immune responses, including the regulation of T cell responses and the development of neurodegenerative diseases. It is a critical regulator of the negative side of the immune response, ensuring that immune cells are able to recognize and eliminate foreign invaders while minimizing the impact on the body's tissues.

One of the most significant functions of LECT2 is its role in regulating the development and differentiation of T cells. T cells are a crucial part of the immune system and play a major role in fighting off infections and diseases. LECT2 is involved in the regulation of T cell receptor (TCR) function, which is critical for T cell activation and differentiation.

In addition to its role in T cell regulation, LECT2 is also involved in the development and progression of neurodegenerative diseases. neurodegenerative diseases are a group of diseases that are characterized by the progressive loss of brain cells and the development of progressive neurological symptoms. LECT2 has has been shown to be involved in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

LECT2 has also been identified as a potential drug target (or biomarker) due to its unique structure and its involvement in several disease processes. LECT2 has a unique farnesylated cysteine 鈥嬧?媟esidue, which is a hallmark of protein stability and is involved in the regulation of protein stability and half-life. In addition, LECT2 also has a unique N-terminus that is rich in conserved hypothetical farnesylated cysteine 鈥嬧?媟esidues, which are involved in protein-protein interactions and may be a potential target for small molecules.

In conclusion, LECT2 is a protein that is expressed in various tissues of the body and is involved in the immune response and the development and progression of neurodegenerative diseases. Its unique structure and its involvement in several disease processes make it an attractive target for small molecules and other therapeutic approaches. Further research is needed to fully understand the role of LECT2 in the immune response and the development of neurodegenerative diseases, as well as to develop effective treatments.

Protein Name: Leukocyte Cell Derived Chemotaxin 2

Functions: Has a neutrophil chemotactic activity. Also a positive regulator of chondrocyte proliferation (PubMed:9524238). Does not show metalloendopeptidase activity (PubMed:27334921)

The "LECT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LECT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets